BioWorld

Oct. 13, 2003

Stock Winners and Losers For The Week

Clinical Trials Update: September 2003

Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: September 2003

FDA Submissions, Approvals And Other Actions: September 2003

BioWorld Stock Report For Public Biotechnology Companies

Cialis Marketing, Price Strategy Puts New Spin On Battle In ED

Money might not buy love but, as Pfizer Inc.'s blockbuster Viagra proved, it can do wonders for sexual capability in men who have the wherewithal to pay for the magic blue pill. Talk about "hard cash." (BioWorld Financial Watch) Read More

Money Raised Year To Date

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...